These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24574970)

  • 21. Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies.
    Comerota MM; Tumurbaatar B; Krishnan B; Kayed R; Taglialatela G
    Mol Neurobiol; 2019 May; 56(5):3341-3355. PubMed ID: 30120733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies.
    Florenzano F; Veronica C; Ciasca G; Ciotti MT; Pittaluga A; Olivero G; Feligioni M; Iannuzzi F; Latina V; Maria Sciacca MF; Sinopoli A; Milardi D; Pappalardo G; Marco S; Papi M; Atlante A; Bobba A; Borreca A; Calissano P; Amadoro G
    Oncotarget; 2017 Sep; 8(39):64745-64778. PubMed ID: 29029390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
    Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
    J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model.
    Wan HL; Hong XY; Zhao ZH; Li T; Zhang BG; Liu Q; Wang Q; Zhao S; Wang JZ; Shen XF; Liu GP
    Theranostics; 2021; 11(11):5511-5524. PubMed ID: 33859760
    [No Abstract]   [Full Text] [Related]  

  • 25. 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy.
    Jiang S; Sydney EJ; Runyan AM; Serpe R; Srikanth M; Figueroa HY; Yang M; Myeku N
    Front Cell Neurosci; 2024; 18():1338502. PubMed ID: 38638303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease.
    Dengler-Crish CM; Smith MA; Wilson GN
    J Alzheimers Dis; 2017; 55(4):1605-1619. PubMed ID: 27814296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
    Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
    Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.
    Duggal P; Mehan S
    J Alzheimers Dis Rep; 2019 Jul; 3(1):179-218. PubMed ID: 31435618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin.
    Hu Y; Li XC; Wang ZH; Luo Y; Zhang X; Liu XP; Feng Q; Wang Q; Yue Z; Chen Z; Ye K; Wang JZ; Liu GP
    Oncotarget; 2016 Apr; 7(14):17356-68. PubMed ID: 26943044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PINK1 Alleviates Cognitive Impairments
    Jiang XJ; Wu YQ; Ma R; Chang YM; Li LL; Zhu JH; Liu GP; Li G
    Front Cell Dev Biol; 2021; 9():736267. PubMed ID: 35059394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction of microtubule defects within Aβ plaque-associated dystrophic axons results in lowered Aβ release and plaque deposition.
    Yao Y; Nzou G; Alle T; Tsering W; Maimaiti S; Trojanowski JQ; Lee VM; Ballatore C; Brunden KR
    Alzheimers Dement; 2020 Oct; 16(10):1345-1357. PubMed ID: 32918367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simulation of synaptic depression, posttetanic potentiation, and presynaptic facilitation of synaptic potentials from sensory neurons mediating gill-withdrawal reflex in Aplysia.
    Gingrich KJ; Byrne JH
    J Neurophysiol; 1985 Mar; 53(3):652-69. PubMed ID: 2580065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presynaptic induction and expression of homosynaptic depression at Aplysia sensorimotor neuron synapses.
    Armitage BA; Siegelbaum SA
    J Neurosci; 1998 Nov; 18(21):8770-9. PubMed ID: 9786984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nogo-A Drives Alzheimer's Disease Progression by Inducing Tauopathy Vulnerability.
    Wang Z; Pan JP; Geng J; Lv S; Chen G; Fang N; Zhang Z; Li J; Xu X; Wang R; Zheng Q; Yan L; Chen G; Xiao F
    Aging Dis; 2024 May; ():. PubMed ID: 38916730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice.
    Gratuze M; Josset N; Petry FR; Pflieger M; Eyoum Jong L; Truchetti G; Poitras I; Julien J; Bezeau F; Morin F; Samadi P; Cicchetti F; Bretzner F; Planel E
    Brain Res; 2019 May; 1711():106-114. PubMed ID: 30641037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling.
    Yin Y; Gao D; Wang Y; Wang ZH; Wang X; Ye J; Wu D; Fang L; Pi G; Yang Y; Wang XC; Lu C; Ye K; Wang JZ
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3773-81. PubMed ID: 27298345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.
    Barron MR; Gartlon J; Dawson LA; Atkinson PJ; Pardon MC
    Front Immunol; 2020; 11():293. PubMed ID: 32194553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.
    Dejanovic B; Huntley MA; De Mazière A; Meilandt WJ; Wu T; Srinivasan K; Jiang Z; Gandham V; Friedman BA; Ngu H; Foreman O; Carano RAD; Chih B; Klumperman J; Bakalarski C; Hanson JE; Sheng M
    Neuron; 2018 Dec; 100(6):1322-1336.e7. PubMed ID: 30392797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
    Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
    Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.